Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia

Not Applicable

Conditions: Fibromyalgia

Interventions: Drug: Tetrahydrocannabinol
Drug: Placebo

First Posted Date: 2010-06-23

Last Posted Date: 2010-06-23

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 80

Registration Number: NCT01149018

Locations: 🇮🇱
Pain Relief Unit, Hadassah Medical Organisation, Jerusalem, Israel

Marinol in Trichotillomania or Obsessive Compulsive Disorder

Phase 2

Completed

Conditions: Obsessive Compulsive Disorder
Trichotillomania

Interventions: Drug: Dronabinol

First Posted Date: 2010-03-26

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 14

Registration Number: NCT01093976

Locations: 🇺🇸
Ambulatory Research Center, Minneapolis, Minnesota, United States

Antagonist-Elicited Cannabis Withdrawal

Phase 1

Completed

Conditions: Cannabis
Dependence

First Posted Date: 2009-12-31

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT01041170

Locations: 🇺🇸
National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States
🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States

Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

Phase 1

Completed

Conditions: Cannabis Abuse
Dependence
Pharmacokinetics
fMRI
Cannabis

First Posted Date: 2009-12-23

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 108

Registration Number: NCT01037608

Locations: 🇺🇸
National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States

Combined Pharmacotherapy for Cannabis Dependency

Phase 2

Completed

Conditions: Cannabis Dependence
Marijuana Dependence

Interventions: Drug: Placebo
Drug: Dronabinol
Drug: Lofexidine

First Posted Date: 2009-11-25

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 156

Registration Number: NCT01020019

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)

Phase 4

Conditions: Posttraumatic Stress Disorders

Interventions: Drug: Tetrahydrocannabinol
Other: Placebo

First Posted Date: 2009-08-26

Last Posted Date: 2012-10-30

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 70

Registration Number: NCT00965809

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

Phase 3

Completed

Conditions: Central Neuropathic Pain in Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2009-08-14

Last Posted Date: 2012-02-03

Lead Sponsor: Bionorica Research GmbH

Target Recruit Count: 240

Registration Number: NCT00959218

Locations: 🇩🇪
Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie, Luedenscheid, Germany

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

Phase 1

Completed

Conditions: Cannabis Use Disorder
Psychotic Disorder
Schizophrenia
Dual Diagnosis
Schizoaffective Disorder

Interventions: Drug: Dronabinol
Drug: Cannabis

First Posted Date: 2009-07-27

Last Posted Date: 2021-07-12

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 12

Registration Number: NCT00946348

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

Sativex for Treatment of Chemotherapy Induced Neuropathic Pain

Phase 3

Completed

Conditions: Neuropathic Pain

Interventions: Drug: Sativex

First Posted Date: 2009-03-31

Last Posted Date: 2014-03-07

Lead Sponsor: Mary Lynch

Target Recruit Count: 16

Registration Number: NCT00872144

Locations: 🇨🇦
Queen Elizabeth II Health Sciences Centre, Pain Management Unit, Halifax, Nova Scotia, Canada

Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)

Not Applicable

Completed

Conditions: Cramps
Amyotrophic Lateral Sclerosis

First Posted Date: 2008-12-22

Last Posted Date: 2009-02-19

Lead Sponsor: Cantonal Hospital of St. Gallen

Target Recruit Count: 24

Registration Number: NCT00812851

Locations: 🇨🇭
Kantonsspital St.Gallen, St.Gallen, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy